Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,392 total articles

Gilat to Report First Quarter 2026 Results on Wednesday, May 13th

Gilat to Report First Quarter 2026 Results on Wednesday, May 13th

Gilat Satellite Networks Ltd., a leader in satellite networking technology, announced it will release its first quarter 2026 financial results on May 13, 2026. The company will host conference calls and webcasts in English and Hebrew to discuss the results and business achievements. Gilat's portfolio includes advanced satellite communication soluti…

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

Pasithea Therapeutics announced that the FDA has granted Rare Pediatric Disease Designation (RPDD) to its drug candidate PAS-004 for the treatment of Neurofibromatosis Type 1 (NF1). This designation supports the drug's potential to address this serious pediatric condition affecting approximately 115,000 individuals in the U.S. PAS-004 already holds…

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

Radiopharm Theranostics announced encouraging initial findings from the Phase 0/1 HEAT clinical trial evaluating 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical, showing meaningful tumor uptake and a favorable safety profile at the lowest 30 mCi dose. The Data Safety and Monitoring Committee has approved advancing to a higher 130 m…

U.S. Energy Corp. Closes Expanded Senior Secured Debt Facility, Completing Phase 1 Capital Stack for Big Sky Carbon Hub; Formally Suspends Use of Equity Line of Credit

U.S. Energy Corp. Closes Expanded Senior Secured Debt Facility, Completing Phase 1 Capital Stack for Big Sky Carbon Hub; Formally Suspends Use of Equity Line of Credit

U.S. Energy Corp. announced the closing of an expanded $20 million senior secured debt facility, together with proceeds from a recent equity offering, expected to complete the Phase 1 capital stack for its Big Sky Carbon Hub. The funding provides financial visibility for Phase 1 construction with commercial operations targeted for Q1 2027. The comp…

TransAlta Appoints Mike Politeski as Chief Financial Officer and Grant Arnold as Chief Commercial Officer

TransAlta Appoints Mike Politeski as Chief Financial Officer and Grant Arnold as Chief Commercial Officer

TransAlta Corporation announced key leadership changes with Mike Politeski joining as EVP and CFO and Grant Arnold as EVP and Chief Commercial Officer, effective May 2026. These appointments coincide with Joel Hunter ascending to President and CEO, following the retirement of John Kousinioris. The new executives bring extensive experience in financ…

Brady Corporation to Acquire Honeywell’s Productivity Solutions and Services Business, Expanding Portfolio with Data Capture and Workflow Solutions

Brady Corporation to Acquire Honeywell’s Productivity Solutions and Services Business, Expanding Portfolio with Data Capture and Workflow Solutions

Brady Corporation announced the acquisition of Honeywell's Productivity Solutions and Services (PSS) business in an all-cash transaction valued at approximately $1.4 billion. The acquisition expands Brady’s product portfolio into leading-edge mobility, scanning, and software solutions that serve enterprise customers in logistics, manufacturing, war…

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

Monte Rosa Therapeutics presented preclinical data at the AACR 2026 Annual Meeting showcasing the potential of MRT-55811, a first-in-class cyclin E1 (CCNE1)-directed molecular glue degrader. The compound demonstrated strong tumor regression in CCNE1-amplified models of ovarian, breast, and gastric cancers with superior selectivity and reduced off-t…

NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality

NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality

NRx Pharmaceuticals welcomes President Trump's Executive Order aimed at accelerating the development and approval of psychedelic medications for treating serious mental illnesses such as depression, PTSD, and suicidality. The company’s drug candidate NRX-100 has received FDA Fast Track designation and anticipates submitting a New Drug Application w…

Kustom Entertainment, Inc. Announces Reverse Stock Split

Kustom Entertainment, Inc. Announces Reverse Stock Split

Kustom Entertainment, Inc. declared a 1-for-5 reverse stock split of its common stock effective April 22, 2026, to raise its share price above Nasdaq's $1.00 minimum requirement. The reverse split includes a proportional reduction in authorized common shares, aiming to ensure continued listing on Nasdaq. The company specializes in advanced video re…

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

Pharvaris announced presentation of clinical data supporting the safety of combined use of deucrictibant immediate-release capsules and extended-release tablets for prophylactic and on-demand treatment of bradykinin-mediated angioedema, including hereditary angioedema (HAE). The data suggest adequate safety margins and potential efficacy for this c…

B2Gold Announces Agreement to Sell its 70% Interest in Fingold Joint Venture to Agnico Eagle for US$325 million; B2Gold and Agnico Eagle to Enter into Nunavut Collaboration Agreement

B2Gold Announces Agreement to Sell its 70% Interest in Fingold Joint Venture to Agnico Eagle for US$325 million; B2Gold and Agnico Eagle to Enter into Nunavut Collaboration Agreement

B2Gold Corp. announced the sale of its 70% interest in the Fingold Ventures Ltd. joint venture to Agnico Eagle Mines Limited for US$325 million in cash. Alongside this transaction, the companies have agreed to collaborate on gold mining operations in Nunavut, Canada, aiming to share expertise and improve operational efficiencies in arctic environme…

Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics

Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics

Silo Pharma highlights its lead program, SPC-15, an intranasal serotonin 4 receptor agonist targeting prophylactic treatment of PTSD, coinciding with President Trump's executive order accelerating psychedelic therapy research. SPC-15 benefits from rapid nose-to-brain delivery and a streamlined regulatory pathway, positioning the company to leverage…

OwlTing Group (NASDAQ: OWLS) Announces 12-Month Lock-Up Extension Supported by SBI and Legacy Shareholders Representing More Than 99% of Subject Shares

OwlTing Group (NASDAQ: OWLS) Announces 12-Month Lock-Up Extension Supported by SBI and Legacy Shareholders Representing More Than 99% of Subject Shares

OwlTing Group, a Nasdaq-listed global fintech company, announced a 12-month extension of lock-up agreements covering over 99% of subject shares, supported by SBI Holdings and legacy shareholders. This move aims to enhance market stability and reflects strong long-term shareholder alignment with OwlTing's strategic focus on expanding its compliant g…

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

Greenwich LifeSciences announced preliminary Phase III FLAMINGO-01 trial data showing statistically significant increased immune response (delayed-type hypersensitivity reactions) in non-HLA-A*02 breast cancer patients treated with GLSI-100, an immunotherapy targeting HER2-expressing cancers. Early analysis suggests a 70-80% reduction in breast can…

USA Rare Earth Announces Definitive Agreement to Acquire Serra Verde Group for ~$2.8 Billion, Creating the Global Rare Earth Leader

USA Rare Earth Announces Definitive Agreement to Acquire Serra Verde Group for ~$2.8 Billion, Creating the Global Rare Earth Leader

USA Rare Earth, Inc. (Nasdaq: USAR) announced a definitive agreement to acquire Serra Verde Group, owner of a key rare earth mine and processing facility in Brazil, for approximately $2.8 billion. This acquisition secures the only large-scale producer outside Asia of all four magnetic rare earth elements critical for advanced technologies. Serra Ve…

Howard Hughes Holdings Appoints Former Arch Capital CEO Marc Grandisson to Company’s Board of Directors

Howard Hughes Holdings Appoints Former Arch Capital CEO Marc Grandisson to Company’s Board of Directors

Howard Hughes Holdings Inc. appointed Marc Grandisson, former CEO of Arch Capital Group Ltd., to its Board of Directors effective May 2026. Grandisson's expertise in specialty insurance and reinsurance comes as Howard Hughes is finalizing its acquisition of Vantage Group Holdings to expand into the insurance sector, marking a strategic pivot for th…

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

Prelude Therapeutics presented preclinical data demonstrating that PRT13722, a novel, orally bioavailable, and highly selective KAT6A degrader, shows potent efficacy and an improved safety profile in multiple models of hormone receptor positive, HER2-negative breast cancer. The data suggest enhanced tumor regression and potential for combination th…

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Oculis Holding AG has announced the completion of the last patient visits in its Phase 3 DIAMOND program evaluating OCS-01, a novel non-invasive topical eye drop treatment for diabetic macular edema (DME). The program includes over 800 patients across two pivotal trials. Topline results are expected in June 2026, with potential NDA submission later…

Supplemental Update Regarding the Board’s Current Pricing Approach for Future M&A-Related Share Issuances

Supplemental Update Regarding the Board’s Current Pricing Approach for Future M&A-Related Share Issuances

Allied Gaming & Entertainment Inc. announced that its Board of Directors has established a disciplined pricing approach for future equity issuances in M&A transactions, setting a reference floor price of $2.00 per share, reflecting the company's asset base and platform value. This approach aims to protect existing shareholders amid ongoing strategi…